FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327752629> ?p ?o ?g. }

• W4327752629 abstract "Abstract Acquired demyelinating syndrome associated with myelin oligodendrocyte glycoprotein antibodies, named recently myelin oligodendrocyte glycoprotein-associated disease, represents &gt;27% of this paediatric syndrome. Relapses occur in 40% of them, which may be associated with severe outcomes. Aiming to identify biomarker allowing to predict relapse, we measured both myelin oligodendrocyte glycoprotein antibodies and neurofilament light chain levels in blood samples of patients that are known to reflect axonal injuries in neurological diseases including demyelinating autoimmune disorders. Three groups of patients were selected: relapsing myelin oligodendrocyte glycoprotein-associated disease (n = 8), non-relapsing myelin oligodendrocyte glycoprotein-associated disease (n = 7) and control patients with non-inflammatory neurological diseases (n = 12). Neurofilament light chain concentrations were measured in plasma of these three groups of patients using the high-sensitivity single-molecule array method at onset of the disease and 6 months later. At onset of the disease, we found that levels of neurofilament light chain in blood of non-relapsing patients were significantly higher than in control patients (means: 98.36 ± 22.66 versus 12.47 ± 2.47 pg/mL, **P &lt; 0.01, Kruskal–Wallis test). The mean neurofilament light chain value in relapsing patients (82.16 ± 38.41 pg/mL) was not significantly different from that in non-relapsing and in control patients. Plasma myelin oligodendrocyte glycoprotein antibody levels were 2.5-fold higher in relapsing than in non-relapsing patients without reaching significance (means: 15.26 ± 4.87 versus 5.96 ± 1.13; two-tailed Mann–Whitney U-test P = 0.119). Plasma neurofilament light chain correlated significantly with myelin oligodendrocyte glycoprotein antibody levels in relapsing (two-tailed Spearman r = 0.8, P = 0.0218) but not in non-relapsing (two-tailed Spearman r = 0.17, P = 0.71). Interestingly, the ratio of neurofilament light chain-to-myelin oligodendrocyte glycoprotein antibodies was significantly lower in relapsing than in non-relapsing patients (means: 5.19 ± 1.61 versus 21.87 ± 6.13; two-tailed Mann–Whitney U-test P = 0.014). These findings suggest that measuring both neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels in patients at onset of demyelinating disease could predict relapse of myelin oligodendrocyte glycoprotein-associated disease." @default.
• W4327752629 created "2023-03-18" @default.
• W4327752629 creator A5019713035 @default.
• W4327752629 creator A5027059447 @default.
• W4327752629 creator A5029220492 @default.
• W4327752629 creator A5031422065 @default.
• W4327752629 creator A5032170909 @default.
• W4327752629 creator A5041774387 @default.
• W4327752629 creator A5056049991 @default.
• W4327752629 creator A5073221474 @default.
• W4327752629 creator A5076172496 @default.
• W4327752629 creator A5088946190 @default.
• W4327752629 date "2023-03-02" @default.
• W4327752629 modified "2023-10-01" @default.
• W4327752629 title "Early blood neurofilament light chain and myelin oligodendrocyte glycoprotein antibody levels associate with different disease courses of myelin oligodendrocyte glycoprotein-associated disease in children" @default.
• W4327752629 cites W1870638711 @default.
• W4327752629 cites W2021593812 @default.
• W4327752629 cites W2044637498 @default.
• W4327752629 cites W2049923210 @default.
• W4327752629 cites W2069311934 @default.
• W4327752629 cites W2093292982 @default.
• W4327752629 cites W2103813255 @default.
• W4327752629 cites W2113812219 @default.
• W4327752629 cites W2119874037 @default.
• W4327752629 cites W2127568644 @default.
• W4327752629 cites W2128597204 @default.
• W4327752629 cites W2129229339 @default.
• W4327752629 cites W2133652987 @default.
• W4327752629 cites W2147089471 @default.
• W4327752629 cites W2150429740 @default.
• W4327752629 cites W2150735552 @default.
• W4327752629 cites W2154982729 @default.
• W4327752629 cites W2206286096 @default.
• W4327752629 cites W2276951055 @default.
• W4327752629 cites W2342233016 @default.
• W4327752629 cites W2545267953 @default.
• W4327752629 cites W2614808368 @default.
• W4327752629 cites W2739773649 @default.
• W4327752629 cites W2740881639 @default.
• W4327752629 cites W2751963214 @default.
• W4327752629 cites W2767386734 @default.
• W4327752629 cites W2769032112 @default.
• W4327752629 cites W2783746308 @default.
• W4327752629 cites W2791164819 @default.
• W4327752629 cites W2800192720 @default.
• W4327752629 cites W2806667920 @default.
• W4327752629 cites W2806791998 @default.
• W4327752629 cites W2884356229 @default.
• W4327752629 cites W2889223700 @default.
• W4327752629 cites W2890238902 @default.
• W4327752629 cites W2902337882 @default.
• W4327752629 cites W2906887292 @default.
• W4327752629 cites W2935678420 @default.
• W4327752629 cites W2939789416 @default.
• W4327752629 cites W2944999308 @default.
• W4327752629 cites W2950228559 @default.
• W4327752629 cites W2966302029 @default.
• W4327752629 cites W2974101629 @default.
• W4327752629 cites W2979502567 @default.
• W4327752629 cites W3002588492 @default.
• W4327752629 cites W3004767455 @default.
• W4327752629 cites W3006216901 @default.
• W4327752629 cites W3006577702 @default.
• W4327752629 cites W3025155289 @default.
• W4327752629 cites W3026936125 @default.
• W4327752629 cites W3042931334 @default.
• W4327752629 cites W3080498270 @default.
• W4327752629 cites W3088999077 @default.
• W4327752629 cites W3129130223 @default.
• W4327752629 cites W3148526428 @default.
• W4327752629 cites W3170578581 @default.
• W4327752629 cites W3212262170 @default.
• W4327752629 cites W4220708455 @default.
• W4327752629 cites W4221085749 @default.
• W4327752629 doi "https://doi.org/10.1093/braincomms/fcad063" @default.
• W4327752629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36993944" @default.
• W4327752629 hasPublicationYear "2023" @default.
• W4327752629 type Work @default.
• W4327752629 citedByCount "0" @default.
• W4327752629 crossrefType "journal-article" @default.
• W4327752629 hasAuthorship W4327752629A5019713035 @default.
• W4327752629 hasAuthorship W4327752629A5027059447 @default.
• W4327752629 hasAuthorship W4327752629A5029220492 @default.
• W4327752629 hasAuthorship W4327752629A5031422065 @default.
• W4327752629 hasAuthorship W4327752629A5032170909 @default.
• W4327752629 hasAuthorship W4327752629A5041774387 @default.
• W4327752629 hasAuthorship W4327752629A5056049991 @default.
• W4327752629 hasAuthorship W4327752629A5073221474 @default.
• W4327752629 hasAuthorship W4327752629A5076172496 @default.
• W4327752629 hasAuthorship W4327752629A5088946190 @default.
• W4327752629 hasBestOaLocation W43277526291 @default.
• W4327752629 hasConcept C108625454 @default.
• W4327752629 hasConcept C126322002 @default.
• W4327752629 hasConcept C142724271 @default.
• W4327752629 hasConcept C153911025 @default.
• W4327752629 hasConcept C157207234 @default.
• W4327752629 hasConcept C159654299 @default.
• W4327752629 hasConcept C203014093 @default.
• W4327752629 hasConcept C204232928 @default.
• W4327752629 hasConcept C2776985911 @default.

• next